| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-965 | |
| Phytochemical name or plant extracts | Solajiangxin H | |
| PMID | 28123569 | |
| Literature evidence | Additionally, the present study provides evidence in support of the hypothesis that S. lyratum may be a promising candidate for the development of novel cancer therapies. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Sesquiterpenoid | |
| Source of phytochemicals or plant Extracts | Solanum lyratum | |
| Geographical availability | Cambodia, China North-Central, China South-Central, China Southeast, Hainan, Japan, Korea, Taiwan, Tibet, Vietnam | |
| Plant parts | Whole plant | |
| Other cancers | Breast cancer, Lung cancer, Stomach cancer, hepatocarcinoma | |
| Target gene or protein | Bcl-2, Survivin, Bcl-2-like 4, Caspase 3, c-Caspase 9 | |
| Gene or Protein evidence | The results of DAPI staining and western blot analysis, used to study the anticancer mechanisms of solajiangxin H and lyratol D in SGC-7901 cells, suggested that solajiangxin H and lyratol D induced the apoptosis of SGC-7901 cells significantly (P<0.01), downregulated the expression of the antiapoptotic proteins B-cell lymphoma (Bcl)-2 and survivin, and upregulated the expression of the proapoptotic proteins Bcl-2-like protein 4, second mitochondria-derived activator of caspase, cleaved (c)-caspase-3 and c-caspase-9. | |
| Target pathways | NA | |
| IC50 | 15.4±0.9 µg/ml against MCF-7 | |
| Potency | NA | |
| Cell line/ mice model | MCF-7, HCT-8, A-549, SGC-7901 and BEL-7402 | |
| Additional information | Additionally, the present study provides evidence in support of the hypothesis that S. lyratum may be a promising candidate for the development of novel cancer therapies. | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:927300-1 | |
| Safety | NA |